Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF 38 3-Year FCF Growth Rate is 50.80% as of Jun. 2026, which is 109% above its 10-year median of 24.30. GuruFocus rates ACIXF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Fairly Valued). The stock has 1 warning sign investors should review. Among 585 Medical Devices & Instruments companies, Acarix AB ranks better than 82.05% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 50.80% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 38.00% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 26.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Acarix AB was 50.80% per year. The lowest was -22.20% per year. And the median was 24.30% per year.
Acarix AB (OTCPK:ACIXF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Acarix AB 3-Year FCF Growth Rate Related Terms
ACIXF vs ABT, SYK, MDT: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, Acarix AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Acarix AB's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 50.80% mean?
Acarix AB (ACIXF) has a 3-Year FCF Growth Rate of 50.80% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Acarix AB and its competitors. This is 109% above median its historical median of 24.30. According to the industry distribution chart, Acarix AB ranks #105 out of 585 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is Acarix AB's 3-Year FCF Growth Rate too high?
Acarix AB's current 3-Year FCF Growth Rate of 50.80% is 109% above median its 10-year median of 24.30. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Acarix AB's value of 50.80% is 182.2% above this industry median. Based on the distribution chart, Acarix AB ranks #105 out of 585 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 3-Year FCF Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #105 out of 585 companies for 3-Year FCF Growth Rate. This places Acarix AB in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 18.00. Acarix AB's value of 50.80% is 182.2% above this benchmark. While the company's 10-year median is 24.30 vs. the industry median of 18.00, Acarix AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current 3-Year FCF Growth Rate of 50.80% is 182.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current 3-Year FCF Growth Rate is 50.80%, which is 109% above median its own 10-year median of 24.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 0.5% below its estimated fair value. The current 3-Year FCF Growth Rate is 50.80%, which is 109% above median its 10-year median of 24.30 and 182.2% above the Medical Devices & Instruments industry median of 18.00. Acarix AB's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Acarix AB (ACIXF), the current 3-Year FCF Growth Rate is 50.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be undervalued.
The current stock price of $0.02 is trading 0.5% below its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Fairly Valued.
Key valuation signals for ACIXF:
3-Year FCF Growth Rate: 50.80% (109% above median its 10-year median of 24.30)
GF Value™: $0.02 vs. price of $0.02 (0.5% below fair value)
Industry Position: 182.2% above the Medical Devices & Instruments median (#105 of 585)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
38GF Score
Get the complete analysis for ACIXF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
